Form 10-Q KalVista Pharmaceuticals For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Leerink Partners Reiterates Outperform Rating on Kalvista Pharmaceuticals Inc (KALV)
September 6, 2024 6:35 AM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and $20.00 price target on Kalvista Pharmaceuticals Inc (NASDAQ: KALV).
The analyst comments "Bottom Line: We are updating our model following the disclosure of KALV's F1Q financial results and corporate update; the FDA recently accepted sebetralstat's NDA with a PDUFA goal date of June 17, 2025. The company continues to advance lead asset sebetralstat (KVD900), an oral plasma kallikrein inhibitor, towards a commercial launch for the on-demand treatment of... More
